SG11201803153RA - Oxadiazaspiro compounds for the treatment of drug abuse and addiction - Google Patents
Oxadiazaspiro compounds for the treatment of drug abuse and addictionInfo
- Publication number
- SG11201803153RA SG11201803153RA SG11201803153RA SG11201803153RA SG11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA SG 11201803153R A SG11201803153R A SG 11201803153RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- compounds
- barcelona
- addiction
- drug abuse
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 May 2017(26.05.2017) WIPOIPCT (10) International Publication Number WO 2017/084752 A1 (51) International Patent Classification: C07D 498/10 (2006.01) A61P 25/34 (2006.01) A61K 31/5386 (2006.01) A61P 25/36 (2006.01) A61P 25/32 (2006.01) (21) International Application Number: PCT/EP2016/001907 (22) International Filing Date: (25) Filing Language: (26) Publication Language: 15 November 2016 (15.11.2016) English English (30) Priority Data: 15382566.6 16 November 2015 (16.11.2015) EP (71) Applicant: LABORATORIOS DEL DR. ESTEVE, S.A. [ES/ES]; Avda. Mare de Deu de Montserrat 221, 08041 Barcelona (ES). (72) Inventors: VIRGILI-BERNADO, Marina; c/Baldiri Reixac 10, 08028 Barcelona (ES). ALMANSA-ROS- ALES, Carmen; C/Teodora Lamadrid no. 41, Ent. 4a, 08022 Barcelona (ES). ALEGRET-MOLINA, Carlos; C/Baldiri Reixac 10, 08028 Barcelona (ES). (74) Agents: PETERS, Hajo et al.; Zacco GmbH, Bayerstrasse 83, 80335 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) < n Tf 00 n O (54) Title: OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION (57) : The present invention relates to compounds having pharmacological activity towards the sigma (o) receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular against drug abuse and addiction.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15382566 | 2015-11-16 | ||
| PCT/EP2016/001907 WO2017084752A1 (en) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803153RA true SG11201803153RA (en) | 2018-06-28 |
Family
ID=54707728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803153RA SG11201803153RA (en) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10927128B2 (en) |
| EP (1) | EP3377500B1 (en) |
| JP (1) | JP6884974B2 (en) |
| KR (1) | KR20180080327A (en) |
| CN (1) | CN108349999A (en) |
| AR (1) | AR106697A1 (en) |
| AU (1) | AU2016356488B2 (en) |
| BR (1) | BR112018009279A8 (en) |
| CA (1) | CA3002286A1 (en) |
| CO (1) | CO2018004665A2 (en) |
| DK (1) | DK3377500T3 (en) |
| ES (1) | ES2932000T3 (en) |
| HR (1) | HRP20221343T1 (en) |
| HU (1) | HUE060275T2 (en) |
| IL (1) | IL259035B (en) |
| LT (1) | LT3377500T (en) |
| MA (1) | MA43250B1 (en) |
| MX (1) | MX2018005439A (en) |
| MY (1) | MY193423A (en) |
| PH (1) | PH12018500814A1 (en) |
| PL (1) | PL3377500T3 (en) |
| PT (1) | PT3377500T (en) |
| RS (1) | RS63734B1 (en) |
| SG (1) | SG11201803153RA (en) |
| SI (1) | SI3377500T1 (en) |
| TN (1) | TN2018000122A1 (en) |
| TW (1) | TWI756196B (en) |
| UA (1) | UA123775C2 (en) |
| WO (1) | WO2017084752A1 (en) |
| ZA (1) | ZA201802845B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018005439A (en) | 2015-11-16 | 2018-11-09 | Esteve Labor Dr | Oxadiazaspiro compounds for the treatment of drug abuse and addiction. |
| WO2020157026A1 (en) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| WO2023041713A1 (en) | 2021-09-20 | 2023-03-23 | Esteve Pharmaceuticals, S.A. | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4244961A (en) * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents |
| US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
| WO2005075484A2 (en) * | 2004-02-10 | 2005-08-18 | F. Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
| WO2005084678A1 (en) | 2004-03-03 | 2005-09-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
| WO2006022454A1 (en) * | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | Compound containing basic group and use thereof |
| EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
| CN101228127B (en) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | Novel piperidine derivative |
| CN101203567A (en) * | 2005-06-07 | 2008-06-18 | 西巴特殊化学品控股有限公司 | Scratch resistant polyolefin |
| DE102005030051A1 (en) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | New substituted 1-oxo-3,8-diazospiro(4.5)-decan-2-one compounds are 5-hydroxy tryptamine uptake receptor inhibitors, useful to treat and/or prevent e.g. pain, migraine, chronic paroxysomal hemicrania, depression and asthma |
| AU2006303437B2 (en) | 2005-10-19 | 2012-06-28 | Grunenthal Gmbh | Novel vanilloid receptor ligands and their use for producing medicaments |
| ES2407115T3 (en) | 2005-11-18 | 2013-06-11 | Ono Pharmaceutical Co., Ltd. | Compound containing a basic group and its use |
| EP1829869A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
| EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
| MX2009009355A (en) | 2007-03-01 | 2009-09-11 | Mitsubishi Tanabe Pharma Corp | Benzimidazole compound and pharmaceutical use thereof. |
| EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
| EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| JP2010538003A (en) | 2007-08-29 | 2010-12-09 | グラクソスミスクライン エルエルシー | Thiazole and oxazole kinase inhibitors |
| EP2070933A1 (en) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Tricyclic triazolic compounds |
| EP2242759B1 (en) | 2008-02-06 | 2012-09-12 | AstraZeneca AB | Compounds |
| EP2108643A1 (en) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist |
| GB201016912D0 (en) * | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
| AU2012229187B2 (en) | 2011-03-14 | 2016-11-10 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
| WO2013052716A1 (en) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| JPWO2013115294A1 (en) * | 2012-01-31 | 2015-05-11 | 東レ株式会社 | Diaza spiro urea derivative and its pharmaceutical use |
| EP3027625B1 (en) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure |
| TW201615642A (en) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | Amide derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| TW201615643A (en) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | Alkyl and aryl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| TWI685497B (en) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
| WO2016122994A1 (en) | 2015-01-29 | 2016-08-04 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
| MX2018005439A (en) | 2015-11-16 | 2018-11-09 | Esteve Labor Dr | Oxadiazaspiro compounds for the treatment of drug abuse and addiction. |
-
2016
- 2016-11-15 MX MX2018005439A patent/MX2018005439A/en unknown
- 2016-11-15 PL PL16797458.3T patent/PL3377500T3/en unknown
- 2016-11-15 MA MA43250A patent/MA43250B1/en unknown
- 2016-11-15 BR BR112018009279A patent/BR112018009279A8/en active Search and Examination
- 2016-11-15 SI SI201631621T patent/SI3377500T1/en unknown
- 2016-11-15 HR HRP20221343TT patent/HRP20221343T1/en unknown
- 2016-11-15 HU HUE16797458A patent/HUE060275T2/en unknown
- 2016-11-15 PT PT167974583T patent/PT3377500T/en unknown
- 2016-11-15 TN TNP/2018/000122A patent/TN2018000122A1/en unknown
- 2016-11-15 CN CN201680066748.9A patent/CN108349999A/en active Pending
- 2016-11-15 WO PCT/EP2016/001907 patent/WO2017084752A1/en active Application Filing
- 2016-11-15 EP EP16797458.3A patent/EP3377500B1/en active Active
- 2016-11-15 MY MYPI2018701503A patent/MY193423A/en unknown
- 2016-11-15 DK DK16797458.3T patent/DK3377500T3/en active
- 2016-11-15 LT LTEPPCT/EP2016/001907T patent/LT3377500T/en unknown
- 2016-11-15 US US15/774,407 patent/US10927128B2/en active Active
- 2016-11-15 AR ARP160103486A patent/AR106697A1/en unknown
- 2016-11-15 AU AU2016356488A patent/AU2016356488B2/en active Active
- 2016-11-15 JP JP2018524257A patent/JP6884974B2/en active Active
- 2016-11-15 KR KR1020187017092A patent/KR20180080327A/en not_active Application Discontinuation
- 2016-11-15 UA UAA201806353A patent/UA123775C2/en unknown
- 2016-11-15 RS RS20221052A patent/RS63734B1/en unknown
- 2016-11-15 SG SG11201803153RA patent/SG11201803153RA/en unknown
- 2016-11-15 CA CA3002286A patent/CA3002286A1/en active Pending
- 2016-11-15 TW TW105137236A patent/TWI756196B/en active
- 2016-11-15 ES ES16797458T patent/ES2932000T3/en active Active
-
2018
- 2018-04-16 PH PH12018500814A patent/PH12018500814A1/en unknown
- 2018-04-30 CO CONC2018/0004665A patent/CO2018004665A2/en unknown
- 2018-04-30 IL IL259035A patent/IL259035B/en active IP Right Grant
- 2018-04-30 ZA ZA2018/02845A patent/ZA201802845B/en unknown
-
2020
- 2020-12-21 US US17/128,738 patent/US11649248B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201807778YA (en) | Bicyclic compounds for diagnosis and therapy | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201809126RA (en) | Aromatic sulfonamide derivatives | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201809799WA (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| SG11201809702SA (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201807977XA (en) | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases |